Multiple Myeloma and AL Amyloidosis in a Renal Transplant Recipient

Aparicio, Michel; Précigout, V. De; Reiffers, J; Déminière, C.; Morel, Delphine; Merville, Pierre; Bouchet, Jean-Louis; Potaux, L

doi:10.1159/000185784

Cited by 19 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We believe that this is the first report demonstrating de novo AL amyloid deposition in the renal allograft. We have found only one potentially similar case in the literature -that of a renal transplant patient who had concurrent multiple myeloma and AL amyloidosis [3]. However, in that case, there was no amyloid deposition identified in the allograft kidney at autopsy.…”

Section: Discussionmentioning

confidence: 91%

De novo AL Amyloid in a Renal Allograft

Lê

Wood²,

Alpers³

1998

Am J Nephrol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

De novo AL Amyloid in a Renal Allograft

Lê

Wood²,

Alpers³

1998

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…Among 11 patients tested, EBV in situ hybridization was positive in seven cases [14–16,18,19, 21,24], suggesting the virus played a role in disease development. Thirteen patients developing MM after KT have been reported in case reports from 1983 to 2011, but no conclusion could be made about their particularities and prognosis [25–28]. Recently, Safadi et al [29] reported seven cases of MM occurring after KT between 2001 and 2012.…”

Section: Introductionmentioning

confidence: 99%

Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature

et al. 2017

View full text Add to dashboard Cite

Although post-transplant lymphoproliferative disorder (PTLD) is the second most common type of cancer in kidney transplantation (KT), plasma cell neoplasia (PCN) occurs only rarely after KT, and little is known about its characteristics and evolution. We included twenty-two cases of post-transplant PCN occurring between 1991 and 2013. These included 12 symptomatic multiple myeloma, eight indolent myeloma and two plasmacytomas. The median age at diagnosis was 56.5 years and the median onset after transplantation was 66.7 months (2–252). Four of the eight indolent myelomas evolved into symptomatic myeloma after a median time of 33 months (6–72). PCN-related kidney graft dysfunction was observed in nine patients, including six cast nephropathies, two light chain deposition disease and one amyloidosis. Serum creatinine was higher at the time of PCN diagnosis than before, increasing from 135.7 (±71.6) to 195.9 (±123.7) μmol/l (p = 0.008). Following transplantation, the annual rate of bacterial infections was significantly higher after the diagnosis of PCN, increasing from 0.16 (±0.37) to 1.09 (±1.30) (p = 0.0005). No difference was found regarding viral infections before and after PCN. Acute rejection risk was decreased after the diagnosis of PCN (36% before versus 0% after, p = 0.004), suggesting a decreased allogeneic response. Thirteen patients (59%) died, including twelve directly related to the hematologic disease. Median graft and patient survival was 31.7 and 49.4 months, respectively. PCN after KT occurs in younger patients compared to the general population, shares the same clinical characteristics, but is associated with frequent bacterial infections and relapses of the hematologic disease that severely impact the survival of grafts and patients.

show abstract

“…The occur rence of, at least transient, mono-or oligoclonal bands in the transplant population has been noted by several in vestigators [38,39], but the progression to myeloma is uncommon. Sheil et al [40] found 1 case among over 4,000 patients in the Australian and New Zealand Dialysis and Transplant Register, and only 3 other cases have been reported [41][42][43]. There is no good explanation for the disparity between the incidence of lymphomas, mainly of B cell origin, and myelomas, both clonal disorders in volving B cells, but one suggestion has been the relatively young age of the transplant recipients.…”

Section: Maintenance Renal Replacement Therapymentioning

confidence: 99%